If the higher dose MPL repeats the same up to almost 5 year life extension that was shown in Phase 1 with an excellent safety profile, wouldn’t approval be a given? Even if these figures in Phase 2/3 weren’t as “good” as our Phase 1?
Ann: Board Changes, page-175
-
- There are more pages in this discussion • 76 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
-0.005(2.50%) |
Mkt cap ! $86.77M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.0¢ | 19.5¢ | $99.41K | 503.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 431735 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 28192 | 2 |
View Market Depth
| Last trade - 14.18pm 05/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |